Triple-Negative Breast Cancer: Perspectives on the Disparities in Care and Managed Care Considerations for the Advancing Treatment Paradigm

Physicians and nurses seeking CE credit are encouraged to register with our partner, Physicians Education Resource (https://www.gotoper.com) and view this activity at https://education.gotoper.com//activity/tnbc21ccatp.

Program Description
Triple-negative breast cancer (TNBC) is aggressive and has the highest rate of metastatic disease and lowest survival rate compared with other breast cancer subtypes. Treatment is challenging due to disease complexity, with available therapies including cytotoxic chemotherapies, PARP inhibitors, immunotherapies, and antibody therapy. There are also disparities to overcome in the treatment of TNBC, as clinical outcomes are impacted by both biologic and nonbiologic factors in various ethnic groups. This activity will explore the clinical data and guideline recommendations for the treatment of TNBC as well as strategies for formulary management. Additionally, panelists will share insights with participants to promote awareness of potential racial disparities in cancer care.

Target Audience: Managed care and oncology pharmacists
Type of Activity: Application
Release date: October 29, 2021
Expiration date: October 29, 2022

Time to complete activity: 1.5 hours

Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Explore the epidemiology and clinical guideline treatment recommendations for triple-negative breast cancer (TNBC) as well as challenges to care

• Investigate clinical data of new and emerging immunotherapies in the treatment of TNBC

• Analyze the impact of racial disparities on treatment outcomes for patients with TNBC as well as strategies to improve access to care

• Identify strategies for managed care professionals to incorporate TNBC therapies into health-system formularies

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-21-373-H01-P. The activity is available for CE credit through October 29, 2022.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Physicians’ Education Resource®, LLC, and Pharmacy Times Continuing Education™. Physicians’ Education Resource®, LLC is accredited by the ACCME to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, view the panel discussion in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

The following contributors have no relevant financial relationships with commercial interests to disclose:

Faculty

Danielle Roman, PharmD, BCOP, Allison Schepers, PharmD, BCOP, Laura R. Bobolts, PharmD, BCOP, and Marielle Fares, PharmD

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Meg Croom Taylor, PharmD, CPP; Kelly McCormick; Susan Pordon; Brianna Winters; and Chloe Taccetta

An anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms